**Finch** is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. Human-First Discovery platform Our platform is built to rapidly translate insights mined from compelling human data into the development of novel microbiome therapeutics. > [!info] Our Collaborators > We believe that collaboration is key to unlocking the full potential of the microbiome. As such, we have partnerships with leading clinician researchers and institutions driving human microbiome research around the globe—from the United States to Australia and China. We are also proud to partner with [[Takeda|Takeda Pharmaceuticals]] on the development of microbiome therapeutics for individuals with [[Ulcerative Colitis|ulcerative colitis]] and [[Crohn's Disease|Crohn’s disease]], the most common types of [[Inflammatory Bowel Disease|inflammatory bowel disease (IBD)]]. Our partnership, initially focused on the development of TAK-524 (previously known as FIN-524) for ulcerative colitis, was expanded in 2019 to include the initial development of a potential microbiome product candidate, FIN-525, for Crohn’s disease. Takeda’s deep expertise in gastroenterology and IBD is an ideal complement to our own expertise in microbiome therapeutics. > > Source: [Finch Therapeutics | About](https://www.finchtherapeutics.com/about/)